Cargando…
Clinical Characteristics and Long-term Follow-up of Patients with Diabetes Due To PTF1A Enhancer Mutations
CONTEXT: Biallelic mutations in the PTF1A enhancer are the commonest cause of isolated pancreatic agenesis. These patients do not have severe neurological features associated with loss-of-function PTF1A mutations. Their clinical phenotype and disease progression have not been well characterized. OBJ...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526731/ https://www.ncbi.nlm.nih.gov/pubmed/32893856 http://dx.doi.org/10.1210/clinem/dgaa613 |
_version_ | 1783588925055434752 |
---|---|
author | Demirbilek, Huseyin Cayir, Atilla Flanagan, Sarah E Yıldırım, Ruken Kor, Yılmaz Gurbuz, Fatih Haliloğlu, Belma Yıldız, Melek Baran, Rıza Taner Akbas, Emine Demet Demiral, Meliha Ünal, Edip Arslan, Gulcin Vuralli, Dogus Buyukyilmaz, Gonul Al-Khawaga, Sara Saeed, Amira Al Maadheed, Maryam Khalifa, Amel Onal, Hasan Yuksel, Bilgin Ozbek, Mehmet Nuri Bereket, Abdullah Hattersley, Andrew T Hussain, Khalid De Franco, Elisa |
author_facet | Demirbilek, Huseyin Cayir, Atilla Flanagan, Sarah E Yıldırım, Ruken Kor, Yılmaz Gurbuz, Fatih Haliloğlu, Belma Yıldız, Melek Baran, Rıza Taner Akbas, Emine Demet Demiral, Meliha Ünal, Edip Arslan, Gulcin Vuralli, Dogus Buyukyilmaz, Gonul Al-Khawaga, Sara Saeed, Amira Al Maadheed, Maryam Khalifa, Amel Onal, Hasan Yuksel, Bilgin Ozbek, Mehmet Nuri Bereket, Abdullah Hattersley, Andrew T Hussain, Khalid De Franco, Elisa |
author_sort | Demirbilek, Huseyin |
collection | PubMed |
description | CONTEXT: Biallelic mutations in the PTF1A enhancer are the commonest cause of isolated pancreatic agenesis. These patients do not have severe neurological features associated with loss-of-function PTF1A mutations. Their clinical phenotype and disease progression have not been well characterized. OBJECTIVE: To evaluate phenotype and genotype characteristics and long-term follow-up of patients with PTF1A enhancer mutations. SETTING: Twelve tertiary pediatric endocrine referral centers. PATIENTS: Thirty patients with diabetes caused by PTF1A enhancer mutations. Median follow-up duration was 4 years. MAIN OUTCOME MEASURES: Presenting and follow-up clinical (birthweight, gestational age, symptoms, auxology) and biochemical (pancreatic endocrine and exocrine functions, liver function, glycated hemoglobin) characteristics, pancreas imaging, and genetic analysis. RESULTS: Five different homozygous mutations affecting conserved nucleotides in the PTF1A distal enhancer were identified. The commonest was the Chr10:g.23508437A>G mutation (n = 18). Two patients were homozygous for the novel Chr10:g.23508336A>G mutation. Birthweight was often low (median SDS = –3.4). The majority of patients presented with diabetes soon after birth (median age of diagnosis: 5 days). Only 2/30 presented after 6 months of age. All patients had exocrine pancreatic insufficiency. Five had developmental delay (4 mild) on long-term follow-up. Previously undescribed common features in our cohort were transiently elevated ferritin level (n = 12/12 tested), anemia (19/25), and cholestasis (14/24). Postnatal growth was impaired (median height SDS: –2.35, median BMI SDS: –0.52 SDS) with 20/29 (69%) cases having growth retardation. CONCLUSION: We report the largest series of patients with diabetes caused by PTF1A enhancer mutations. Our results expand the disease phenotype, identifying recurrent extrapancreatic features which likely reflect long-term intestinal malabsorption. |
format | Online Article Text |
id | pubmed-7526731 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-75267312020-10-05 Clinical Characteristics and Long-term Follow-up of Patients with Diabetes Due To PTF1A Enhancer Mutations Demirbilek, Huseyin Cayir, Atilla Flanagan, Sarah E Yıldırım, Ruken Kor, Yılmaz Gurbuz, Fatih Haliloğlu, Belma Yıldız, Melek Baran, Rıza Taner Akbas, Emine Demet Demiral, Meliha Ünal, Edip Arslan, Gulcin Vuralli, Dogus Buyukyilmaz, Gonul Al-Khawaga, Sara Saeed, Amira Al Maadheed, Maryam Khalifa, Amel Onal, Hasan Yuksel, Bilgin Ozbek, Mehmet Nuri Bereket, Abdullah Hattersley, Andrew T Hussain, Khalid De Franco, Elisa J Clin Endocrinol Metab Clinical Research Articles CONTEXT: Biallelic mutations in the PTF1A enhancer are the commonest cause of isolated pancreatic agenesis. These patients do not have severe neurological features associated with loss-of-function PTF1A mutations. Their clinical phenotype and disease progression have not been well characterized. OBJECTIVE: To evaluate phenotype and genotype characteristics and long-term follow-up of patients with PTF1A enhancer mutations. SETTING: Twelve tertiary pediatric endocrine referral centers. PATIENTS: Thirty patients with diabetes caused by PTF1A enhancer mutations. Median follow-up duration was 4 years. MAIN OUTCOME MEASURES: Presenting and follow-up clinical (birthweight, gestational age, symptoms, auxology) and biochemical (pancreatic endocrine and exocrine functions, liver function, glycated hemoglobin) characteristics, pancreas imaging, and genetic analysis. RESULTS: Five different homozygous mutations affecting conserved nucleotides in the PTF1A distal enhancer were identified. The commonest was the Chr10:g.23508437A>G mutation (n = 18). Two patients were homozygous for the novel Chr10:g.23508336A>G mutation. Birthweight was often low (median SDS = –3.4). The majority of patients presented with diabetes soon after birth (median age of diagnosis: 5 days). Only 2/30 presented after 6 months of age. All patients had exocrine pancreatic insufficiency. Five had developmental delay (4 mild) on long-term follow-up. Previously undescribed common features in our cohort were transiently elevated ferritin level (n = 12/12 tested), anemia (19/25), and cholestasis (14/24). Postnatal growth was impaired (median height SDS: –2.35, median BMI SDS: –0.52 SDS) with 20/29 (69%) cases having growth retardation. CONCLUSION: We report the largest series of patients with diabetes caused by PTF1A enhancer mutations. Our results expand the disease phenotype, identifying recurrent extrapancreatic features which likely reflect long-term intestinal malabsorption. Oxford University Press 2020-09-07 /pmc/articles/PMC7526731/ /pubmed/32893856 http://dx.doi.org/10.1210/clinem/dgaa613 Text en © Endocrine Society 2020. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Research Articles Demirbilek, Huseyin Cayir, Atilla Flanagan, Sarah E Yıldırım, Ruken Kor, Yılmaz Gurbuz, Fatih Haliloğlu, Belma Yıldız, Melek Baran, Rıza Taner Akbas, Emine Demet Demiral, Meliha Ünal, Edip Arslan, Gulcin Vuralli, Dogus Buyukyilmaz, Gonul Al-Khawaga, Sara Saeed, Amira Al Maadheed, Maryam Khalifa, Amel Onal, Hasan Yuksel, Bilgin Ozbek, Mehmet Nuri Bereket, Abdullah Hattersley, Andrew T Hussain, Khalid De Franco, Elisa Clinical Characteristics and Long-term Follow-up of Patients with Diabetes Due To PTF1A Enhancer Mutations |
title | Clinical Characteristics and Long-term Follow-up of Patients with Diabetes Due To PTF1A Enhancer Mutations |
title_full | Clinical Characteristics and Long-term Follow-up of Patients with Diabetes Due To PTF1A Enhancer Mutations |
title_fullStr | Clinical Characteristics and Long-term Follow-up of Patients with Diabetes Due To PTF1A Enhancer Mutations |
title_full_unstemmed | Clinical Characteristics and Long-term Follow-up of Patients with Diabetes Due To PTF1A Enhancer Mutations |
title_short | Clinical Characteristics and Long-term Follow-up of Patients with Diabetes Due To PTF1A Enhancer Mutations |
title_sort | clinical characteristics and long-term follow-up of patients with diabetes due to ptf1a enhancer mutations |
topic | Clinical Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526731/ https://www.ncbi.nlm.nih.gov/pubmed/32893856 http://dx.doi.org/10.1210/clinem/dgaa613 |
work_keys_str_mv | AT demirbilekhuseyin clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT cayiratilla clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT flanagansarahe clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT yıldırımruken clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT koryılmaz clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT gurbuzfatih clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT haliloglubelma clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT yıldızmelek clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT baranrızataner clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT akbaseminedemet clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT demiralmeliha clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT unaledip clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT arslangulcin clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT vurallidogus clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT buyukyilmazgonul clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT alkhawagasara clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT saeedamira clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT almaadheedmaryam clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT khalifaamel clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT onalhasan clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT yukselbilgin clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT ozbekmehmetnuri clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT bereketabdullah clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT hattersleyandrewt clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT hussainkhalid clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations AT defrancoelisa clinicalcharacteristicsandlongtermfollowupofpatientswithdiabetesduetoptf1aenhancermutations |